Weekly Recap | XLV.US +0.17%, closing in on record highs
I'm LongbridgeAI, I can summarize articles.The Health Care Select Sector SPDR (XLV) rose 0.17% this week to close at $171.45, roughly in line with the S&P 500’s +0.09% gain and ahead by about 0.08 percentage points. The week was choppy: the fund dipped to $169.20 on Monday, rallied through Tuesday and Wednesday to a weekly high of $174.483, then faded on Thursday and Friday to finish at $171.45. The weekly range was 3.1%, and average daily volume of about 7.
The Week
The Health Care Select Sector SPDR (XLV) rose 0.17% this week to close at $171.45, roughly in line with the S&P 500’s +0.09% gain and ahead by about 0.08 percentage points. The week was choppy: the fund dipped to $169.20 on Monday, rallied through Tuesday and Wednesday to a weekly high of $174.483, then faded on Thursday and Friday to finish at $171.45. The weekly range was 3.1%, and average daily volume of about 7.0m shares sat roughly 26% below the median, pointing to comparatively thin trading. The fund remains just below its recent range high of $176.595 from mid-August.
Sector News
Healthcare news flow was dense this week, centring on drug approvals, clinical data and dealmaking. Gilead Sciences won FDA approval for a new single-tablet HIV regimen and reported progress in HIV and breast cancer research. Abbott’s TactiFlex Duo ablation catheter showed positive late-breaking data in complex AFib cases. AbbVie posted positive Phase 3 CERVINO results and completed its acquisition of Apogee Therapeutics.
On the deal side, Novartis agreed to pay up to $3.2bn for Alteogen’s drug delivery technology, Eli Lilly struck a deal worth up to $2.88bn for Merdia Biosciences, and Pfizer signed a co-development and licensing agreement with Medicus Pharma for a CD228V antibody-drug conjugate. On the regulatory front, the UK regulator suspended Amgen’s Tavneos for new patients over unreliable data, adding pressure to that rare-disease asset.
The Week Ahead
Macro data and Treasury auctions dominate next week’s calendar and will shape the rate-sensitive healthcare tape. NFIB small business optimism arrives Tuesday. Thursday brings jobless claims, final demand PPI, core final demand PPI, existing home sales, wholesale sales, and the 10-year Treasury auction with its high yield and bid-to-cover ratio. If PPI prints hot or the auction yield climbs, longer-duration healthcare exposure could face headwinds; softer readings would likely ease that pressure.
In Short
Healthcare held up this week on the back of innovation news and deal activity, with XLV edging higher and outperforming the broad market slightly. The fund trades at about 17.2x earnings and 1.33x book, a relatively moderate valuation. In the latest session, large-lot flow was a net buyer at 4,981.70, while mid and small lots were net sellers at 5,360.54 and 5,703.63 respectively, leaving an internal tension between institutional accumulation and retail distribution. Next week’s PPI and 10-year auction will determine the direction of rate expectations and, with it, the sector’s valuation anchor.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.